Deal Details

Sale to Chiltern International Inc.

---

Summary

About

Theorem Clinical Research Holdings Inc. (“Theorem” or the “Company”), a portfolio company of Nautic Partners LLC (“Nautic”), was acquired by Chiltern International Inc. (“Chiltern”). Terms of the transaction were not disclosed.

Theorem is a global provider of comprehensive clinical services with staff throughout the Americas, Europe and Asia-Pacific and a client base comprised of the world’s leading biopharmaceutical and medical device companies. With industry-leading experts, unparalleled therapeutic expertise and innovative, groundbreaking technology, Theorem is focused on analytic-based development, combination trials and personal data applications to simplify complex trials. Theorem is headquartered in King of Prussia, Pennsylvania.

Nautic is a private equity firm that targets equity investments of $25 to $75 million. It seeks majority ownership in niche businesses with strong market share and growth potential, identified value enhancement opportunities and strong management teams. Areas of focus include business services, manufacturing and healthcare. Nautic is based in Providence, Rhode Island and has managed over $3 billion of assets during its 29 year history.

Chiltern is a leading global CRO that listens to client needs in order to customize solutions for the biopharma industry. With 34 years in service, Chiltern delivers from three specialized business units: Chiltern Biopharma, with deep therapeutic expertise in respiratory, anti-infectives/vaccines, ophthalmology, dermatology and other specialty areas; Chiltern Oncology, led by physicians, scientists and clinicians to uniquely manage all phases of hematologic and oncologic clinical drug development; and Chiltern Source, a world leader in tailored relationships for FSP, resourcing and staffing solutions. Chiltern’s 2,200 engaged professionals work across 45 countries to deliver flexible, responsive solutions that are “Designed Around You.” Chiltern is headquartered in Slough, United Kingdom.

---

For additional information about this transaction, please contact: